MICHAEL JAMES OVERMAN to Protein Kinase Inhibitors
This is a "connection" page, showing publications MICHAEL JAMES OVERMAN has written about Protein Kinase Inhibitors.
Connection Strength
0.139
-
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019 02 01; 30(2):243-249.
Score: 0.054
-
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs. 2015 Aug; 33(4):977-84.
Score: 0.042
-
EGFR-targeted therapies in colorectal cancer. Dis Colon Rectum. 2007 Aug; 50(8):1259-70.
Score: 0.024
-
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63.
Score: 0.009
-
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. 2013 Oct; 31(5):1375-83.
Score: 0.009